2009
DOI: 10.1016/j.jaad.2008.11.910
|View full text |Cite
|
Sign up to set email alerts
|

Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment tool

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
126
1
5

Year Published

2011
2011
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 126 publications
(139 citation statements)
references
References 45 publications
3
126
1
5
Order By: Relevance
“…1) PPP is a chronic, relapsing skin disease characterized by sterile intraepidermal pustules and usually scaly erythematous skin on the palm, soles, or both. 13) The etiology of PPP has not yet been clarified. In addition to metal allergy, many factors, such as tonsillitis, dental complications, and smoking status, have been reported to cause or exacerbate PPP.…”
Section: Discussionmentioning
confidence: 99%
“…1) PPP is a chronic, relapsing skin disease characterized by sterile intraepidermal pustules and usually scaly erythematous skin on the palm, soles, or both. 13) The etiology of PPP has not yet been clarified. In addition to metal allergy, many factors, such as tonsillitis, dental complications, and smoking status, have been reported to cause or exacerbate PPP.…”
Section: Discussionmentioning
confidence: 99%
“…Çalışmamızda fototerapi tercih edilme oranlarının daha az bulunması hatalarımızın ortalama PAŞİ değerlerinin düşüklüğü ile açıklanabilir. Palmoplantar psoriasis konvansiyonel tedavilere çoğunlukla dirençli, hastalarda belirgin morbiditeye neden olan psoriazis tipidir [22]. Tedavide sistemik tedavilere ek olarak lokal PUVA ve lokal DBUVB tedavisi de kullanılmaktadır [23].…”
Section: Discussionunclassified
“…Tratamentos sistêmicos para a PPP têm mostrado eficácia limitada quando comparados a outras lesões psoriasiformes 11 . Em adultos, o tratamento inclui fototerapia, fotoquimioterapia e agentes sistêmicos como retinóides, metotrexato, ciclosporina e agentes biológicos, como alefacept, infliximab, adalimumab e efalizumab 5,10,14 . Contudo, estudos sobre o uso prolongado, toxicidade sistêmica e experiência clínica em crianças são limitados e escassos, o que dificulta o uso seguro dessas opções terapêuticas nessa faixa etária 8 .…”
Section: Discussionunclassified